Adjunctive Molecular Hydrogen Therapy Modulates T Cell Markers and Reduces Anti-Ro Antibody in Refractory Oral Ulcers of Behçet’s Disease and Sjögren’s Syndrome: A Case Report.
Lin CC, Lu JW, Ho YJ, Lui SW, Hsieh TY, Wang KY, Liu FC · In vivo (Athens, Greece) · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Adjunctive Molecular Hydrogen Therapy Modulates T Cell Markers and Reduces Anti-Ro Antibody in Refractory Oral Ulcers of Behçet’s Disease and Sjögren’s Syndrome: A Case Report.” is organized in H2HUBB under the research focus injected hydrogen oral health study 2026. The publication is cited as Lin CC, Lu JW, Ho YJ, Lui SW, Hsieh TY, Wang KY, Liu FC, In vivo (Athens, Greece), 2026. This case report or case series examined Adjunctive Molecular Hydrogen Therapy Modulates T Cell Markers and Reduces Anti-Ro Antibody in Refractory Oral Ulcers of Behçet’s Disease and Sjögren’s Syndrome: A Case Report. The abstract describes Human participants; hydrogen delivered as injected or infused hydrogen. The abstract reports: Molecular hydrogen may aid refractory oral ulcers in Behçet's and primary Sjögren's syndromes, with clinical and immunologic benefits. This is an automated editorial draft based on the abstract and requires source review before publication.
Injected hydrogen oral health study 2026 overview
Behçet's Disease is a systemic vasculitis affecting both venous and arterial vessels, characterized by painful oral and genital ulcers. Primary Sjögren's Syndrome is an… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.
Study design and hydrogen intervention
Publication type: Case report or case series. Evidence type: Human clinical evidence. Research model or population: Human participants. Blinding: Unknown. Control status: Unknown.
Delivery method: Injected or infused hydrogen.
Reported findings and scientific interpretation
For this injected hydrogen oral health study 2026, the study record reports the following: The abstract reports: Molecular hydrogen may aid refractory oral ulcers in Behçet's and primary Sjögren's syndromes, with clinical and immunologic benefits.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: Case-report evidence cannot establish causality or broad generalizability.
Safety: The abstract did not provide detailed safety or adverse-event information.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.